InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (5 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Moyes Jay M, Director. Insider active across 3 companies, notably Puma Biotechnology, INC.. In total, 13 disclosures have been logged. Split: 2 buys · 5 sells. Total volume traded: €508k. History available since 10 June 2021. The latest transaction was disclosed on 23 February 2026 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Moyes Jay M
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
1,000 shares@ US$2.9121.0% of flowCommon StockSEC:0001493152-26-007964:0
Canonical exit: 24 May 2026 (T+90)
3,000 shares@ US$3.5854100.0% of flowCommon StockSEC:0001493152-25-012367:0
Canonical exit: 24 Nov 2025 (T+90)
22,000 shares@ US$3.4013.0% of flowCommon StockSEC:0001437749-25-020715:0
27,000 shares0Common StockSEC:0001437749-25-020361:0
27,000 shares0Common StockSEC:0001437749-24-021016:0
22,000 shares@ US$3.339410.3% of flowCommon StockSEC:0001437749-24-020568:0
22,000 shares@ US$3.453210.6% of flowCommon StockSEC:0001437749-23-017610:0
32,800 shares0Class A Common StockSEC:0001534969-23-000017:0
22,858 shares@ US$2.64110.016% mcap10.8% of flowCommon StockSEC:0001437749-22-015524:0
27,000 shares0Common StockSEC:0001437749-22-015294:0
2,455 sharesClass A Common StockSEC:0001104659-21-094520:0
27,858 shares0Common StockSEC:0001209191-21-041706:0
25,248 shares@ US$11.361737.2% of flowCommon StockSEC:0001209191-21-039954:0
13 of 13 declarations
About Moyes Jay M
Administrator, MOYES JAY M has reported 13 filings. In the sampled recent filings, the amounts are EUR 11,700 of purchases and EUR 496,207 of sales, with transactions ranging from 2021-06-11 to 2026-02-25. The main filings concern Puma Biotechnology, INC. and Sintx Technologies, Inc.
